Trimodal therapy approaches for localized rectal cancer continue to evolve as new data helps define how to best improve outcomes while reducing adverse effects, with total neoadjuvant therapy among the approaches of recent interest. Clinicians can benefit from education on relevant clinical trial results related to trimodal therapy for localized rectal cancer and guidance on how these data may be best applied to clinical practice.
Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and will benefit from a comprehensive review of the novel treatments for cutaneous melanoma.
This tumor board will discuss how to select the most appropriate therapy for patients with non-small cell lung cancer (NSCLC) using a case-based format. New targeted therapy regimens are being rapidly approved for patients with metastatic NSCLC and have been shown to improve outcomes for these patients.
This program features world-renowned experts who will review the current standard of care for patients with breast cancer, the latest NCCN Guidelines recommendations, and recent clinical research updates.
While relatively rare, biliary tract cancers have a poor prognosis. Recently, molecular profiling has become increasingly useful as some new targeted therapies received FDA approval. It is important for clinicians to keep abreast of new and upcoming therapies in order to develop an optimal treatment strategy.
Pharmacists should be aware of the new data and recommendations surrounding this novel agent and how they relate to improvements in patient survival and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies.
Pharmacists should be aware of the treatment recommendations for this rare disease type so they can support patients as well as the health care team in making informed treatment decisions. It is also important to be aware of the potential adverse events that can occur with these therapies since pharmacists frequently provide patient education and monitoring related to this in order to avoid severe complications and maximize treatment outcomes.
It is important to provide education and an action plan to outline how exercise may not only reduce side effects from chemotherapy but also help chemotherapy work better and improve survival. As new data emerges, more specific exercise “doses” can be prescribed.
Marginal zone lymphomas (MZLs) represent a clinical challenge due to their heterogeneity, and the relative rarity of individual subtypes has largely precluded the use of standard treatment approach across all subtypes. Educating clinicians about the biology of MZLs, novel therapeutic approaches, and special considerations will help them to develop an individualized treatment plan to optimize clinical outcomes.
In order to optimize patient outcomes, clinicians need to understand the evidence behind the current recommendations in the guidelines, the rationale for appropriate treatment selection, management of any treatment- or MM-specific adverse events, and emerging strategies.

Pages

Subscribe to RSS - Live Webinar